Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience

YAGI Yu, KANEMASA Yusuke, SASAKI Yuki, HAYASHI Yudai, MINO Mano, KATO Chika, SAKAI Satoshi, OHIGASHI An, KANBARA Yasuhiro, MORITA Yuka, TAMURA Taichi, ATSUTA Yuya, KONUMA Ryosuke, NAKAMURA Shohei, WADA Atsushi, OKUYA Toshihiro, KAGEYAMA Akihiko, MURAKAMI Daisuke, NAKASHIMA Shiori, UCHIBORI Yusuke, ONAI Daishi, HAMAMURA Atsushi, NISHIJIMA Akihiko, OMURO Yasushi, SHINGAI Naoki, SHIMIZUGUCHI Takuya, TOYA Takashi, SHIMIZU Hiroaki, NAJIMA Yuho, KOBAYASHI Takeshi, HARAGUCHI Kyoko, OHASHI Kazuteru, DOKI Noriko, OKUYAMA Yoshiki, SHIMOYAMA Tatsu

doi:10.11406/rinketsu.63.1363

<p>Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the approach to patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This study retrospectively analyzed patients treated with commercially available tisagenlecleucel at our hospital and evaluated its safety and effectiveness. Of the 21 patients evaluated, any grade and grade ≥3 cytokine release syndrome (CRS) occurred in 85.7% and 9.5% of the patients, respectively. A total of 66.7% received tocilizumab and 28.6% received glucocorticoids for the treatment of CRS. The complete response (CR) rate at 3 months was 61.9% (95% confidence interval [CI] 38.4-81.9). After a median follow-up of 6.3 months following CAR-T infusion, the progression-free survival (PFS) and overall survival rates at 6 months were 53.1% (95%CI 28.3-72.7) and 69.2% (95%CI 43.7-84.9), respectively. Severe cytopenia and hypogammaglobulinemia occurred frequently following CAR-T infusion. Eight patients (38.1%) had comorbidities that would have made them ineligible for leukapheresis in the JULIET trial. However, the presence of comorbidities at the time of leukapheresis had no significant effect on the rates of CR, PFS, and adverse events. Tisagenlecleucel for r/r DLBCL in the real-world setting showed high efficacy and manageable safety profile comparable with the pivotal trial.</p>

Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience

Bibliographic Information

Search this article

Abstract

Journal

Keywords

Details 詳細情報について

Export

Report a problem

Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience

Bibliographic Information

Search this article

Abstract

Journal

Keywords

Details 詳細情報について

Export

Report a problem

Project list